SynthesisClinical rheumatology2026
Efficacy and safety of interventions for Fibromyalgia syndrome comorbid with Irritable bowel syndrome: systematic review.
Synthesis in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibromyalgia syndrome (FMS) and irritable bowel syndrome (IBS) frequently coexist, compounding disease burden and complicating treatment approaches. Despite the prevalence of this comorbidity, evidence on effective management strategies remains scarce.
objectiveThis systematic review evaluates the efficacy and safety of oral pharmacological and dietary interventions for patients diagnosed with both FMS and IBS, following PRISMA guidelines.
methodsA systematic literature search was performed on September 12, 2024, utilizing the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (PubMed), Web of Science, EMBASE, and Ovid to identifying randomized control trials evaluating interventions for FMS comorbid with IBS. The outcome encompassed pain reduction, global well-being, depressive symptoms, health-related quality of life, and safety profiles.
resultsThe initial search yielded 784 studies, with 364 retrieved after applying inclusion criteria. Following duplicate removal and further screening, five randomized control trials met eligibility criteria. Of these, three were included in the meta-analysis. These trials investigated the effects of pharmacological agents, dietary modifications, and probiotics on pain and quality-of-life measures in patients with FMS-IBS comorbidity. Meta-analysis showed a statistically significant reduction in pain Visual Analog Scale (VAS) scores in groups receiving cyclobenzaprine and pregabalin, while probiotics demonstrated no significant benefit over placebo. Dietary interventions showed mixed results, providing symptom relief in selected patients. Adverse effects were highest in the cyclobenzaprine 30 mg group but were generally well tolerated in other interventions.
conclusionPharmacological treatments appear effective in reducing pain associated with FMS and IBS. Dietary interventions, such as monosodium glutamate (MSG) elimination, may benefit specific subgroups, while probiotics showed limited efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.